Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DisTinGuish: DKN-01 + tislelizumab ± chemotherapy in gastric/GEJ adenocarcinoma
2023-504940-32-00Phase 2Completed
- Sponsor
- Leap Therapeutics, Inc.
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of sirexatamab and tislelizumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (4 arms), sponsored by Leap Therapeutics, Inc. Primary endpoints: Safety and tolerability (Parts A & B) and Progression-free survival in DKK1-high patients (Part C primary). Started Jul 2023; status: completed.
02
Drugs
sirexatamabtislelizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2023-504940-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504940-32-00.